Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The fourth-quarter 2024 earnings season will kick off this week, with banking sector players due to report numbers. The ...

Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Netflix's "Squid Game" season two delves deeper into the staff hierarchy, defined by mask shapes and ranks. It reveals their roles correlated with the Korean alphabet. The show continues its global ...